Awareness through advocacy and education (1:00 pm – 1:50 pm)
Chairs: Nelesh Govender (South Africa) and Rosely Zancope (Brazil)
13.00 – 13.08 hrs The CDC view on histoplasmosis (Tom Chiller, USA)
13.08 – 13.16 hrs Ongoing initiatives at PAHO (Freddy Perez, USA)
13.16 – 13.24 hrs How many patients with MDR-TB have histoplasmosis?(David Denning, UK)
13.24 – 13.32 hrs The North-American experience: MSGERC point of view (Nathan Bahr, USA)
13.32 – 13.40 hrs How do we teach histoplasmosis (Ilan Schwartz, USA)
13.40 – 13.50 hrs Q&A
Collaborative research (1:50 pm – 2:50 pm)
Chairs: Ana Alastruey (Spain)
13.50 – 13.58 hrs Brazilian network – Induction and Factorial trial (Alessandro C. Pasqualotto, Brazil)
13.58 – 14.06 hrs A second life for clinical trials biocollections (EVAdiag) (Fanny Lanternier, France)
14.06 – 14.14 hrs Antigen detection in asymptomatic individuals (Thuy Le, Vietnam)
14.14 – 14.22 hrs External validation of a clinical score (Ugo Françoise, French Guiana)
14.22 – 14.30 hrs Argentinian network (Cristina Canteros, Argentina)
14.30 – 14.50 hrs Q&A
Break (2:50 pm – 3:00 pm)
Capacity building in fighting histoplasmosis (3:00 pm – 3:40 pm)
Chairs: Tom Chiller (USA), Juan Luis Tudela (Switzerland)
15.00 – 15.08 hrs FungiRED in Guatemala (Eduardo Arathoon, Guatemala)
15.08 – 15.16 hrs Improving public and private laboratory capacity in Colombia (Beatriz Gomez, Colombia)
15.16 – 15.24 hrs Capacity building in Africa (Rita Oladele, Nigeria)
15.24 – 15.32 hrs FungiCAM project in Cambodia (Aude Sturny Leclere, France)
15.32 – 15.40 hrs Q&A
Access to modern diagnosis and treatment tools (3:40 pm – 4:20 pm)
Chairs: Guillermo Garcia-Effron (Argentina) and Paul Verweij (Netherlands)
15.40 – 15.48 hrs State of the art of access to diagnostics and antifungals in Latin America (Diego Falci, Brazil)
15.48 – 15.56 hrs What is the future of antigen detection for screening, diagnosis and disease follow up? (Juan Luis Tudela Switzerland)
15.56 – 16.04 hrs Shall we consider PCR as a standard of care? (Alexandre Alanio, France)
16.04 – 16.12 hrs Novel technologies for the detection or identification of Histoplasma spp. (Ferry Hagen, The Netherlands)
16.12 – 16.20 hrs Q&A
Histoplasma strains and hosts interactions (4:20 pm – 4:50 pm)
Chairs: Gordon Brown (UK), Claire Hoving (South Africa)
16.20 – 16.28 hrs Update on molecular epidemiology of histoplasmosis and considerations regarding its impact in clinics (Bernardo Guerra Tenório, Brazil)
16.28 – 16.36 hrs Pathophysiology and relevant targets for clinicians (Allan Guimarães, Brazil)
16.36 – 16.42 hrs What can we learn from histoplasmosis in animals? (Melissa Xavier, Brazil)
16.42 – 16.50 hrs Q&A
Concluding remarks and perspectives (4:50 pm – 5:10 pm)
Alessandro C. Pasqualotto (Brazil), Antoine Adenis (French Guiana)
OUR SPONSORS
